Tech Company Financing Transactions
Sangart Funding Round
Sangart closed a $50 million venture capital round on 4/20/2011. Investors included Leucadia National Corp and private investors.
Transaction Overview
Company Name
Announced On
4/20/2011
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Undisclosed
Investors
Leucadia National Corp (Lead Investor)
Proceeds Purpose
This series G funding will allow us to continue advancing the development of our medicines and get them as quickly as possible to patients in need. We continue to see promise in our MP4-based medicines in the treatment of patients who experience an acute traumatic injury and in patients with sickle cell disease suffering from a vaso-occlusive crisis.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
6175 Lusk Blvd
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Sangart, Inc. is a biopharmaceutical company focused on the research, development and commercialization of oxygen transport agents.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Brian O'Callaghan
Chief Financial Officer
David Renas
Chief Medical Officer
Frank Booth
Chief Operating Officer
Don Brown
Chief Scientific Officer
Kenneth Burhop
VP - Human Resources
Kristine Figueroa
VP - Regulatory Affairs
Carmen Betancourt-Riche
Browse more venture capital transactions:
Prev: 4/20/2011: Link Medicine venture capital transaction
Next: 4/20/2011: Decide.com venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on funding rounds that are announced publicly. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs